Anmeldung erfolgt in Kürze...
Details werden geladen...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | The Manila Times
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ('Iovance' or the 'Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ('TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the 'Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.
Ähnliche Seiten
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/06/06/tmt-newswire/globenewswire/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2359870Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/2350373
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/06/20/tmt-newswire/globenewswire/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/2369285EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2346093Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2357328